[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100587471":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":28,"collaborators":7,"id":32,"slug":33,"hasResults":34,"nctId":35,"briefTitle":36,"officialTitle":37,"acronym":7,"eligibilityCriteria":38,"healthyVolunteers":34,"sex":39,"minAge":40,"maxAge":7,"enrollmentInfo":41,"targetDuration":7,"studyType":44,"phases":7,"briefSummary":45,"conditions":46,"keywords":7,"overallStatus":16,"whyStopped":7,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":59},{"fullName":5,"class":6},"Seoul National University Hospital","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Kyung-Hun Lee, MD, PhD","CONTACT","82-2-2072-7207","kyunghunlee@snu.ac.kr",[15],{"facility":5,"status":16,"city":17,"state":7,"zip":18,"country":19,"countryCode":7,"cosmosGeoPoint":20,"geoPoint":25,"contacts":26},"RECRUITING","Seoul","03080","South Korea",{"type":21,"coordinates":22},"Point",[23,24],126.9784,37.566,{"lat":24,"lon":23},[27],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},{"type":29,"investigatorFullName":30,"investigatorTitle":31,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Kyung-Hun Lee","Principal Investigator","100587471","trastuzumab-emtansinet-dm1-after-trastuzumab-deruxtecant-dxd-in-her2-positive-breast-cancer-in-korea-100587471",false,"NCT06928818","Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea","Prospective Observational Study of Trastuzumab Emtansine Immediately After Trastuzumab Deruxtecan in Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in Korea","Inclusion Criteria:\n\n* HER2-positive, advanced (unresectable locally advanced or metastatic) breast cancer\n* Prior treatment with trastuzumab deruxtecan(T-DXd) in the advanced setting\n* Intention to treat with Trastuzumab Emtansine (T-DM1) as first therapy upon T-DXd progression\n\nExclusion Criteria:\n\n* Any systemic treatment, other than T-DM1, for breast cancer after trastuzumab deruxtecan (As an exception, patients treated with endocrine agents, not in combination with cytotoxics or antibody-drug conjugates, will be permitted in the study)\n* Has been previously treated with T-DM1 for advanced breast cancer\n* Has been previously treated with 4 or more lines of therapy for advanced breast cancer\n\n  * Half (50%) or more patients will be those who were treated with second-line trastuzumab deruxtecan (i.e. patients at the later line will be capped).","ALL","19 Years",{"count":42,"type":43},100,"ESTIMATED","OBSERVATIONAL","Prospective observational study of trastuzumab emtansine immediately after trastuzumab deruxtecan in patients with advanced HER2-positive breast cancer in Korea",[47,48,49],"Cancer of Breast","Trastuzumab Emtansine","Trastuzumab Deruxtecan","2026-04-21",{"date":52,"type":53},"2026-04-23","ACTUAL",{"date":55,"type":53},"2025-02-26",{"date":57,"type":43},"2029-09-30",{"name":5,"class":6},1]